Phaarmasia Limited (BOM:523620)

Market Cap	738.34M
Revenue (ttm)	335.76M
Net Income (ttm)	7.82M
Shares Out	6.83M
EPS (ttm)	1.15
PE Ratio	94.15
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109
Average Volume	4,067
Open	110.35
Previous Close	112.60
Day's Range	110.35 - 110.35
52-Week Range	23.60 - 131.75
Beta	1.11
RSI	52.15
Earnings Date	Nov 14, 2025

About Phaarmasia

Phaarmasia Limited manufactures and sells oral contraceptive pills and iron tablets in India. It offers hormone products, including mifepristone and misoprostaol, desogestrel and ethinyl estradiol, estradiol valerate, levonorgestrel and ethinyl estradiol, medroxyprogesterone acetate, cabergoline, clomiphene citrate, levonorgestrel, progesterone, fluoxymesterone, liothyronine sodium, chlorodehydromethyltestosterone, liothyronine sodium, oxandrolone tablets, testosterone cypionate, methenolone enanthate, drostanolone, testosterone, trenbolone, an...

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 36
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 523620

Financial Performance

In 2024, Phaarmasia's revenue was 243.69 million, a decrease of -20.35% compared to the previous year's 305.93 million. Losses were -15.89 million, 206.7% more than in 2023.